Floatz logo

Motesanib

Histologically or Cytologically Documented Solid Tumors

AmgenSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Histologically or Cytologically Documented Solid Tumors cohort.

Asset / SponsorPhaseRating
Docetaxel
Amgen
Phase 1CC

Same molecule, other indications

Motesanib is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
pancreatic neuroendocrine tumorDormant
CC
Indicative ·
47 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →